HCV infection in hemophilia A patients is associated with altered cytokines and chemokines profile and might modulate the levels of FVIII inhibitor

Bolina-Santos, Eduarda; Chaves, Daniel Gonçalves; Silva-Malta, Maria Clara Fernandes da; Carmo, Ricardo Andrade; Barbosa-Stancioli, Edel Figueiredo; Martins, Marina Lobato

doi:10.1002/jmv.27432

Cited by 4 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ReA needs to be differentiated from a variety of diseases; patients with joint pain accompanied by fever are easily misdiagnosed as septic arthritis or tuberculous arthritis, which can be excluded according to the history, signs, and results of joint fluid culture. Hemophilia A is an inherited X-linked coagulopathy characterized by low levels or total absence of factor VIII, and hemophilic arthritis (HA) is one of main complications in patients with hemophilia, 17 it also should be considered in the differential diagnosis for ReA. Both of them (ReA and HA) can cause bleeding in the joint cavity, but we considered the former in this case.…”

Section: Discussionmentioning

confidence: 99%

A case of reactive arthritis caused by a perianal abscess

Liu

Zhou

et al. 2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Reactive arthritis is an immune-mediated aseptic arthritis resulting from either genitourinary or intestinal tract in a genetically susceptible host. Reactive arthritis is not uncommon, and the most common infectious agents are Chlamydia trachomatis, Salmonella, Yersinia, and Shigella, some new infectious agents include Staphylococcus lugdunensis, Rothia mucilaginosa, and umbilical cord–derived Wharton’s jelly, as well as the SARS-CoV-2 virus, which has been more studied in recent years. We found that reactive arthritis caused by infection of perianal abscesses is very rare and few cases have been described in the medical literature. We report a 21-year-old man with polyarticular swelling and pain, and subcutaneous hematoma at his right ankle joint; he was considered reactive arthritis. After treating with non-steroidal anti-inflammatory drugs, sulfasalazine, surgery, and antibiotics, the patient’s arthralgia gradually improved and the symptoms largely disappeared at the 1-month follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

A case of reactive arthritis caused by a perianal abscess

Liu

Zhou

et al. 2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

“…Therefore, the use of recombinant FVIII is preferred over FFP to mitigate the risk of transfusion transmitted infections. Another study conducted showed that the use of FFP/cryoprecipitate in severe hemophilia led to HCV infection which has very strong association with low levels of inhibitors 20 . In our study too FFP is associated with inhibitor development.…”

Section: Discussionmentioning

confidence: 99%

Development Of Inhibitors In Hemophilia A Patients Receiving Different Treatment Options

Imitiaz,

Minhas,

Ayesha Younus

et al. 2023

Proceedings S.Z.M.C

View full text Add to dashboard Cite

Introduction: Hemophilia A is the most common inherited bleeding disorder in Pakistan. Apart from frequent bleeds and joint deformities, the formation of inhibitors is the major complication of hemophilia. Inhibitors are antibodies formed against the coagulation factor. The purpose of this study is to determine the incidence of inhibitor development in hemophilia A patient receiving different treatment modalities namely fresh frozen plasma (FFP)/cryoprecipitate, plasma derived FVIII concentrates and long-acting recombinant FVIII concentrates. Aims & Objectives: To assess the development of inhibitors in hemophilia A patients receiving treatment modalities. Place and Duration of Study: The study was conducted at Chughtai Institute of Pathology from November 2021 to November 2023. Material &Methods: A total of 75 registered patients of the Hemophilia Patient Welfare Society, Lahore and Sundas Foundation were initially screened for FVIII inhibitors. Those who were found negative for these inhibitors were included in the study and then divided into three equal groups of 25 patients each. One group received only FFP/cryoprecipitate for treatment, the other group received plasma derived FVIII concentrates and the last group received recombinant factor VIII concentrates. These patients were observed for two years i.e after 15-20 exposures and following this period their inhibitors screening was done again to establish the effect of different treatment modalities on inhibitor development. The data collected was entered and analyzed by SPSS-21, a p-value of ?0.05 was considered significant. Results: Our study showed that only 3 patients out of 25, receiving FFP as treatment modality developed inhibitors. Whereas, none of the patients receiving plasma derived FVIII concentrates and recombinant factor VIII concentrates developed inhibitors. The P value calculated is 0.044 which is significant. Conclusion: Plasma derived FVIII concentrates and recombinant FVIII concentrates are safer as compared to FFP/Cryoprecipitate and have lesser risk for inhibitor development.

show abstract

“…It has been found that patients who are HCV-positive with factor VIII inhibitors have a complex immune profile characterized by higher levels of pro-inflammatory and anti-inflammatory cytokines compared to those who are not [ 4 , 5 ]. The cure rate of chronic hepatitis C has reached 90% with DAA therapy [ 6 ].…”

Section: To the Editormentioning

confidence: 99%